RAPID 1 (52-week study) and RAPID 2 (24-week study) evaluated 2 doses of CIMZIA (200 mg and 400 mg) every 2 weeks in combination with weekly methotrexate (MTX) in adult patients with active rheumatoid arthritis (RA) and an incomplete response to MTX alone.1,2 ACR response data for the CIMZIA 200 mg plus MTX treatment group of RAPID 1 are summarized below.
In RAPID 1, significantly higher ACR response rates were seen with CIMZIA compared with placebo.1 ACR20 response at week 24 was 59% in the CIMZIA 200 mg group compared with 14% for placebo.1 These improvements were sustained through week 52.1,3
Patients treated with CIMZIA are at an increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death. Patients greater than 65 years of age, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants (e.g. corticosteroids or methotrexate) may be at a greater risk of infection.
In RAPID 1, a reduction in signs and symptoms was seen as early as 1 to 2 weeks in some patients with a majority responding by week 12.1 At week 1, 22.9% of patients in the CIMZIA 200 mg group had achieved an ACR20 response, compared with 5.6% in the placebo group.1
At week 12 (peak ACR20 response), 64% of the CIMZIA 200 mg group had achieved an ACR20 response, compared with 18% in the placebo group.1,3 Two-thirds of these responders achieved ACR20 response within the first 6 weeks.3
Similar clinical improvements were seen in RAPID 2.2 As in RAPID 1, significantly higher ACR20 responses were seen with CIMZIA as early as 1 to 2 weeks, with ACR20 response rates peaking at week 12 (64% for CIMZIA vs 13% for placebo).2,4
NEXT: Inhibition of Radiographic Progression »